Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab (anti-Complement C5) can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab (anti-Complement C5) inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab (anti-Complement C5) has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.Purity:>95% (SDS-PAGE&SEC):Endotoxin Level:< 1.0EU/mg. Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
- UPC:
- 51131822
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- Ab182862-100μg
- CAS:
- 1917321-26-6
- Product Size:
- 100μg
